• Home
  • About us
  • Our products
  • Your health
  • Responsibility
  • In the community
  • Research & development
  • Investors
  • Media centre
  • Careers
GlaxoSmithKline logo

Energy consumption

Energy use from our facilities accounts for 66% of GSK’s global warming impact. In 2004, we used 19 million gigajoules of energy - equivalent to the energy consumed in one year by approximately 236,000 UK households. This produced emissions of 1,750 million kg CO2. We bought 41% of our energy as electricity and a small amount (1%) as municipal steam or hot water. The rest was generated from fuel combustion on-site.

In 2004 we developed a draft position statement on our future use of energy, which will be finalised in 2005. This was in response to feedback showing that energy use is a key area of concern among our stakeholders. The draft position sets out a strategy for reducing greenhouse gas emissions through energy efficiency, renewable energy and emissions trading. It also acknowledges that climate change may affect disease patterns and proposes that GSK should support research to help society plan for the consequences of climate change.

In 2004, we continued to work on a number of energy efficiency initiatives. For example, in the UK GSK partnered with the Carbon Trust to reduce energy consumption through energy audits and raising employees’ awareness. In the US we joined the Energy Star programme which encourages businesses to increase their energy efficiency and share best practice.

In the UK, we installed two wind turbines at our Barnard Castle facility.

A number of our UK sites are participating in the government's emissions trading scheme (ETS) - helping us to gain experience in carbon trading. The UK ETS is a voluntary scheme which rewards companies that improve energy efficiency with reductions in the tax they pay on energy consumption. Sites that keep emissions below an agreed target can bank the spare credits to help with compliance in subsequent years or can sell the credits to other participants in the scheme. By the end of 2004, GSK had banked more than 50,000 carbon credits which can be used to help us keep within targets in the future. We plan to participate in the EU Emissions Trading Scheme which began at the start of 2005. We estimate that more than 50% of our carbon dioxide emissions from energy worldwide will be regulated under the EU Scheme.


Energy consumption (excluding transport)
chart: Hazardous Waste Disposed


Year
Steam imported
Electricity imported
Non-transport fuels
(million gigajoules)
2001
0.3
8.1
12.2
2002
0.1
8.2
11.7
2003
0.2
8.2
11.6
2004
0.2
7.8
11.0



Per unit sales as percentage of 2001 baseline
2001
2002
2003
2004
2005
100%
94.1%
92.7%
93.1%
92.0%

* Back to top


Energy consumption by business (Excluding Transport)
chart: Energy consumption by business (Excluding Transport)


Energy consumption by business (Excluding Transport)
Business
2001
2002
2003
2004
(million gigajoules)
01. R&D
5.11
4.80
4.91
4.84
02. Biologicals
1.23
1.22
1.32
1.32
03. Consumer healthcare
1.90
1.90
2.01
2.15
04. New product and global supply
2.03
2.05
2.02
2.04
05. Regional pharma supply
2.03
1.95
1.75
1.77
06. Primary supply and antibiotics
7.93
7.24
6.85
5.77
07. Commercial
0.04
0.63
0.83
0.87
08. Other
0.26
0.21
0.23
0.23

* Back to top


Global warming potential from energy (excluding transport)
chart: Global Warming Potential from Energy (Excluding Transport)

chart: Global Warming Potential from Energy key


Year
Steam imported
Electricity imported
Non-transport fuels
(million kg CO2 equivalent)
2001
37
1,107
748
2002
9
1,116
714
2003
11
1,117
705
2004
11
1,061
677



Per unit sales as percentage of 2001 baseline
2001
2002
2003
2004
2005
100%
93.9%
92.8%
93.1%
92.0%

* Back to top


Global warming potential from energy by business (excluding transport)
chart: Global Warming Potential from Energy by Business (Excluding Transport)


Global warming potential from energy by business (excluding transport)
Business
2001
2002
2003
2004
(million kg CO2 equivalent)
01. R&D
499.71
464.5
474.54
468.49
02. Biologicals
80.75
80.62
86.92
87.61
03. Consumer healthcare
208.27
201.73
208.58
223.73
04. New product and global supply
178.90
180.30
172.51
172.86
05. Regional pharma supply
214.69
205.83
185.29
178.87
06. Primary supply and antibiotics
674.28
623.87
598.57
509.17
07. Commercial
5.99
66.52
88.08
90.16
08. Other
29.37
15.78
18.74
18.77

* Back to top




This section contains information in several formats:

To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.

For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.